The prevention of progression in CKD of medication adherence to AST-120 in patients with non-dialysis chronic kidney disease (CKD) and significance of measurement indoxyl sulfate as an indicator of medication adherence

The prevention of progression in CKD of medication adherence to AST-120 in patients with non-dialysis chronic kidney disease (CKD) and significance of measurement indoxyl sulfate as an indicator of medication adherence - The prevention of progression in CKD of medication adherence to AST-120 in patients with non-dialysis chronic kidney disease (CKD) and significance of measurement indoxyl sulfate as an indicator of medication adherence

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023724

Enrollment

100

Registered

2016-08-24

Start date

2016-08-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-dialysis chronic kidney disease

Interventions

The patient who is already taking AST-120 continues prescription of AST-120. The patient who does not take AST-120 starts prescription of AST-120&lt

6g/day t.i.d. between meals&gt

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Age is >=20 years and obtain written informed consent 2) eGFR<45ml/min/1.73mm2(CKD stage 3b, 4, 5) 3)non-peritoneal dialysis and non-hemodialysis

Exclusion criteria

Exclusion criteria: 1) Patients with a gastrointestinal disorder 2) AFR,RPGN(acute phase), Advanced nephrotic syndrome (albumin<2g/dl), Transplanted kidney 3) Severe heart failure (NYHA3 or more),Serious arrhythmia, Myocardial infarction or PCI within 6 months. 4) T1DM,and T2DM 5) AST, ALT less than 5 times as much as upper limit of standard value. 6) progressive cancer 7) Pregnant or women of childbearing potential unwilling to use effective means of contraception. 8) Patients who cannot signed an informed consent 9) Allergy to AST-120 10) Any other medical conditions disable to comply with the protocol

Design outcomes

Primary

Measure	Time frame
Medication adherence Serum creatinine eGFR indoxyl sulfate(Serum, 24 hour urine)	—

Secondary

Measure	Time frame
BUN Urinany microalbumin Urinany protein NAG B2-Mg	—

Countries

Japan

Contacts

Public ContactHiromichi Yoshizawa

Jichi Medical University Division of Nephrology

zawa-52@jichi.ac.jp028-558-7346

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026